伊犁川宁生物技术股份有限公司

Group 1 - The company raised a total of RMB 1,114 million through the issuance of 222,800,000 shares at a price of RMB 5.00 per share, with a net amount of RMB 1,021.68 million after deducting expenses [2][5][16] - As of December 31, 2024, the company has invested a total of RMB 910.22 million from the raised funds, with specific allocations including RMB 188.54 million for the Shanghai Research Institute project and RMB 196.68 million for the Green Circular Industry Park project [5][16] - The company has established special accounts for the management of raised funds, ensuring compliance with regulatory requirements and protecting investor interests [6][7] Group 2 - The company has adjusted the implementation method of the Shanghai Research Institute project from leasing to purchasing, increasing the investment amount from RMB 200 million to RMB 300 million, with an additional RMB 100 million sourced from over-raised funds [12][13] - The company reported no idle raised funds used for temporary working capital during the reporting period [10] - The company has confirmed that the disclosure of the use of raised funds aligns with actual usage, with no violations reported [13][14] Group 3 - The company plans to distribute a cash dividend of RMB 2.70 per 10 shares, totaling RMB 601.33 million, which represents 42.94% of the net profit attributable to shareholders for the year 2024 [48][49] - The profit distribution plan has been approved by the board and will be submitted for shareholder approval [50][51] - The company will not conduct a capital reserve transfer to increase share capital in 2024 [49]